PetMed Express Inc. (PETS) - Q2 2026 10-Q Summary
Business Context and Reporting Period
PetMed Express, Inc. (PETS) is a direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, food, supplements, and veterinary services. This report covers the quarterly period ended September 30, 2025 (Fiscal Q2 2026). The Company operates under a March 31 fiscal year-end. The financial statements for the comparable prior period (ended September 30, 2024) have been restated to correct material errors regarding the accounting of vendor-funded programs, rebates, and discounts.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 (3 Months) | Q2 2025 (3 Months Restated) | YTD 2026 (6 Months) | YTD 2025 (6 Months Restated) |
|---|---|---|---|---|
| Net Sales | $44,364 | $58,044 | $95,544 | $124,251 |
| Gross Profit | $12,415 | $18,773 | $26,818 | $37,810 |
| Gross Margin % | 28.0% | 32.3% | 28.1% | 30.4% |
| Operating Loss | $(8,380) | $554 | $(42,512) | $4,940 |
| Net Loss | $(8,520) | $2,326 | $(42,672) | $6,080 |
| Adjusted EBITDA | $(2,316) | $2,098 | $(5,012) | $561 |
| Cash & Equivalents | $36,098 | $54,720 (Prior Year End) | N/A | |
| Working Capital | $2,772 | $16,103 (Prior Year End) | N/A |
Note: The YTD 2026 Net Loss includes a non-cash goodwill and intangible asset impairment charge of $27.3 million.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 23.6% quarter-over-quarter and 23.1% year-to-date. This was driven by reduced gross advertising spend, higher consumer promotional usage, and a decline in prescription medication sales. Reorder sales dropped 23.2% and new order sales dropped 26.5%.
- Margin Compression: Gross margin decreased to 28.0% from 32.3% due to higher freight costs and increased promotional activity.
- Expense Increases: General and administrative (G&A) expenses rose 35.1% quarter-over-quarter, primarily due to $2.1 million in professional fees related to a whistleblower investigation and $1.2 million in employee severance.
- Impairment Charges: The Company recorded a $26.7 million goodwill impairment and a $0.6 million intangible asset impairment in the first quarter of fiscal 2026, triggered by downward forecast revisions and a sustained decline in market capitalization.
- Restatement Impact: Prior period results were restated to reclassify certain vendor reimbursements from revenue to cost of sales and to adjust advertising expenses, resulting in lower reported revenue and higher advertising costs for the prior year.
Outlook, Risks, and Unusual Items
- Liquidity: Cash and cash equivalents decreased by $18.6 million over the six-month period. Management believes current cash and expected cash flows are sufficient for operations for at least the next 12 months. The quarterly dividend remains suspended indefinitely.
- Acquisition Proposals: In December 2025, the Company received unsolicited, non-binding acquisition proposals ranging from $4.00 to $4.25 per share. The Board is reviewing these proposals.
- Legal Proceedings: The Company is defending a class-action lawsuit in Pennsylvania regarding alleged "illusory discounts" on product pricing. No liability has been recorded as the outcome is uncertain.
- Internal Controls: The Company has identified unremediated material weaknesses in internal control over financial reporting, related to the accounting errors that necessitated the restatement.
- Stock Rights Plan: A poison pill rights agreement was adopted in December 2024 and extended in November 2025 to expire in December 2026, designed to deter hostile takeovers.
Investor Verification Checklist
- Restatement Details: Verify the specific impact of the accounting restatement on historical comparability and the timeline for remediation of internal control weaknesses.
- Investigation Costs: Monitor the trajectory of professional fees related to the whistleblower investigation and potential future legal settlements.
- Customer Acquisition: Assess the sustainability of the decline in new customer acquisition (down 26.5% QoQ) and the efficiency of marketing spend.
- Acquisition Status: Track the Board's response to the unsolicited acquisition proposals and any potential impact on stock price volatility.
- Cash Burn: Review the rate of cash consumption given the operating losses and the suspension of dividends to ensure liquidity sufficiency.